8-K: Inhibikase Therapeutics Advances IkT-001Pro for Pulmonary Arterial Hypertension Following Positive FDA Feedback

Inhibikase Therapeutics is developing IkT-001Pro, a prodrug of imatinib, for pulmonary arterial hypertension (PAH), with a Phase 2 interim safety readout anticipated in late 2025 or early 2026.

Summary

• Inhibikase Therapeutics is focused on developing innovative medicines, including IkT-001Pro for Pulmonary Arterial Hypertension (PAH).
• IkT-001Pro is a prodrug of imatinib, designed to improve tolerability and reduce side effects associated with imatinib.
• The company has completed clinical studies to quantify imatinib delivery and filed an IND on August 9, 2024, receiving a Study May Proceed letter from the FDA on September 9, 2024.
• A Phase 2 interim safety readout is anticipated in the fourth quarter of 2025 or the first quarter of 2026, with top-line results expected in the fourth quarter of 2026.
• The global addressable market for PAH is estimated to be over $7 billion.
• The company also has Risvodetinib (IkT-148009), a selective c-Abl inhibitor, with Phase 2 results expected in November 2024 for Parkinson's disease and a Phase 3 entry anticipated in 2025.
• The global addressable market for Parkinson's disease is estimated to be over $12 billion.
• The company has a robust patent portfolio for IkT-001Pro, with composition patents extending to 2033, with extensions to 2039, and PAH use patents to 2044.
• The company is planning a Phase 2b trial with 150 patients and a Phase 3 trial with approximately 160 patients, with primary endpoints including pulmonary vascular resistance (PVR) and 6-minute walk distance (6MWD).
• The estimated cost for the Phase 2b and Phase 3 trials is approximately $205 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Inhibikase, highlighting the potential of IkT-001Pro and the company's strong intellectual property position. The company has a clear development plan and is addressing a significant unmet need in PAH. The management team is experienced and the company has received positive feedback from the FDA. However, there are risks associated with clinical trials and regulatory approvals.

Positives

• IkT-001Pro is designed to address the limitations of imatinib by reducing gastrointestinal side effects and improving tolerability.
• The company has received positive feedback from the FDA regarding the development path for IkT-001Pro.
• The company has a strong intellectual property position with patents extending to 2044.
• The company has a highly experienced management team and scientific advisory board.
• The company is targeting a significant unmet need in PAH, where current treatments have limitations.
• The company has a potential for a simpler and faster path to approval using the 505(b)(2) pathway.
• The company has a potential for Breakthrough Designation for IkT-001Pro.
• The company has a clear development plan with defined timelines for clinical trials.

Negatives

• Imatinib, the active ingredient in IkT-001Pro, has a history of adverse events, including subdural hematoma, edema, and gastrointestinal issues.
• The company will need to carefully manage adverse events in clinical trials to ensure patient safety and drug approval.
• The company is reliant on the success of clinical trials to demonstrate the efficacy and safety of IkT-001Pro.
• The company faces competition from other companies developing treatments for PAH.
• The company will need to raise significant capital to fund the clinical development of IkT-001Pro.

Risks

• Clinical trials may not demonstrate the efficacy or safety of IkT-001Pro.
• The company may not be able to obtain regulatory approval for IkT-001Pro.
• The company may face challenges in manufacturing and commercializing IkT-001Pro.
• The company may face competition from other companies developing treatments for PAH.
• The company may not be able to raise sufficient capital to fund its operations.
• The company may experience delays in clinical trials or regulatory approvals.

Future Outlook

The company anticipates a Phase 2 interim safety readout for IkT-001Pro in late 2025 or early 2026, with top-line results expected in late 2026. They also plan to advance Risvodetinib into Phase 3 trials in 2025.

Management Comments

• Marius Hoeper, MD stated, 'Lessons from IMPRES -> Imatinib is an efficacious drug for patients with PAH. With contemporary trial design and Inhibikase's prodrug approach, I believe IkT001-Pro can be a differentiated therapy for patients.'

Industry Context

The development of IkT-001Pro addresses a significant unmet need in PAH, where current treatments have limitations. The company is positioning itself to compete with existing therapies and potentially capture a significant share of the market. The recent approval of Sotatercept highlights the market's interest in disease-modifying therapies for PAH.

Comparison to Industry Standards

• The document compares the efficacy of imatinib in the IMPRES trial to sotatercept in the STELLAR trial, showing comparable improvements in pulmonary vascular resistance and 6-minute walk distance.
• The document highlights that sotatercept only improved disease in 30% of STELLAR participants, indicating a continued unmet need.
• The document notes that inhaled seralutinib has shown less efficacy than sotatercept/imatinib in haemodynamics.
• The document notes that inhaled imatinib (AV-101) has shown no efficacy in Phase 2b studies due to insufficient drug delivery.

Stakeholder Impact

• Shareholders may benefit from the potential success of IkT-001Pro and the company's other pipeline assets.
• Patients with PAH may benefit from a new treatment option with improved tolerability.
• Employees may benefit from the company's growth and success.
• The company's success may have a positive impact on the broader healthcare industry.

Next Steps

• The company plans to initiate a Phase 2b trial for IkT-001Pro.
• The company plans to initiate a Phase 3 trial for IkT-001Pro.
• The company plans to continue development of Risvodetinib, with Phase 3 entry anticipated in 2025.
• The company plans to seek regulatory approval for IkT-001Pro.

Key Dates

Keywords

Pulmonary Arterial Hypertension, PAH, IkT-001Pro, Imatinib, Prodrug, Kinase Inhibitor, Clinical Trials, FDA, Orphan Drug, Risvodetinib, Parkinson's Disease